Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Akari Therapeutics Plc ADR is an American Depositary Receipt representing shares of Akari Therapeutics PLC, a clinical-stage biopharmaceutical company focused on oncology. The company develops next-generation antibody-drug conjugates (ADCs) featuring novel, proprietary payloads that harness powerful biology to target cancer cells precisely. Its lead payload, PH1, disrupts RNA splicing by modulating the spliceosome, a critical cellular mechanism for protein production essential to tumor survival and proliferation. Key pipeline candidates include AKTX-101, which targets the Trop2 receptor prevalent on various cancer cells and uses a proprietary linker for direct delivery of PH1 into tumors, minimizing off-target effects, and AKTX-102, directed at CEACAM5, a validated antigen in multiple solid tumors. Akari Therapeutics PLC operates within the healthcare sector, advancing precision therapies to address unmet needs in cancer treatment. Headquartered in Boston, Massachusetts, it emphasizes bifunctional ADCs designed for enhanced efficacy and safety profiles in solid tumor indications.
$9.52
$1.24 (-11.48%)
EOD Jun 25, 2026 · Twelve Data
Negative free cash flow of -$11M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$28M
▲ +12.6% YoY
Op. Margin
—
ROIC
-35.02%
▲ +16.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$11M
▲ +15.8% YoY
Op. Cash Flow (TTM)
-$10M
▲ +15.8% YoY
Net Debt
-$4M
Net Cash Position
Cash & Equiv.
$5M
Continue Research
Akari Therapeutics Plc ADR (AKTX)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Akari Therapeutics Plc ADR scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Akari Therapeutics Plc ADR scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -35.0% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh AKTX's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.